Merus N.V.
DelistedCIK 1651311fmd_15EFCDAHNN57GR137EY8FXR9D4Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2025, 31 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|
| Total revenues | 38 | 31 | 30 | 49 | 42 | 44 | 36 |
| Research and development | 55 | 56 | 70 | 98 | 149 | 141 | 225 |
| Total operating expenses | 84 | 90 | 106 | 139 | 202 | 200 | 308 |
| Operating income | (46) | (59) | (76) | (90) | (160) | (157) | (272) |
| Interest and investment income | 2 | 2 | 0 | – | – | – | – |
| Other non-operating income (expense) | – | 4 | (9) | 23 | 30 | 5 | 65 |
| Income before taxes | (28) | (55) | (85) | (67) | (130) | (152) | (207) |
| Income tax expense | 0 | 0 | 1 | 0 | 1 | 3 | 8 |
| Net income from continuing operations | (28) | (55) | (86) | (67) | (131) | (155) | (215) |
| Net income | (28) | (55) | (86) | (67) | (131) | (155) | (215) |